Investment Thesis
BiomX faces severe financial distress with negative stockholders' equity of -$1.3M, indicating technical insolvency, combined with persistent operating losses of -$41.5M and negative operating cash flow of -$26.4M. The company's liquidity position is critically strained with a current ratio of 0.87x and long-term debt of $11.2M exceeding total assets of $5.8M, presenting substantial going concern risks.
Strengths
- Maintains $4.4M in cash and equivalents providing short-term runway
- Relatively low current liabilities of $751.1K reducing immediate payment obligations
- Minimal capital expenditure of $2.0K suggests operational discipline
Risks
- Negative stockholders' equity of -$1.3M indicates technical insolvency and balance sheet deterioration
- Operating cash flow burn rate of -$26.4M with no revenue (N/A) suggests unsustainable business model
- Long-term debt of $11.2M significantly exceeds total assets creating severe leverage and refinancing risk
- Current ratio of 0.87x signals acute liquidity stress and short-term solvency concerns
- Negative interest coverage of -48.8x indicates inability to service debt obligations
- Extreme negative ROA of -626% demonstrates value destruction
Key Metrics to Watch
- Cash burn rate and months of runway remaining at current operating cash flow
- Revenue recognition and business operations status
- Debt refinancing or covenant violation announcements
- Stockholders' equity trajectory toward recovery or further deterioration
- Insider buying/selling patterns and management confidence signals
Financial Metrics
Revenue
N/A
Net Income
-36.2M
EPS (Diluted)
$22.19
Free Cash Flow
-26.4M
Total Assets
5.8M
Cash
4.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
N/A
ROA
-626.0%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
0.87x
Quick Ratio
0.87x
Debt/Equity
N/A
Debt/Assets
13.0%
Interest Coverage
-48.78x
Long-term Debt
11.2M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-14T07:06:22.581374 |
Data as of: 2025-12-31 |
Powered by Claude AI